A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerDecentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testCholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancerGenomic profiling in luminal breast cancerUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementPharmacogenetics and pharmacogenomics as tools in cancer therapyHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineIntegration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancerFactors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.Study of integrated heterogeneous data reveals prognostic power of gene expression for breast cancer survival.Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingDouble-edged role of G protein-coupled estrogen receptor 1 in breast cancer prognosis: an analysis of 167 breast cancer samples and online data setsS100β as a serum marker in endocrine resistant breast cancer.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensLate recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.Chemotherapy in early breast cancer: when, how and which one?External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.The innovative evolution of cancer gene and cellular therapies.Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.Equivalence of MammaPrint array types in clinical trials and diagnostics.Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical DecisionsTransfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsMultigene prognostic tests in breast cancer: past, present, futureMarkers for the identification of late breast cancer recurrence.Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Molecular subtyping for clinically defined breast cancer subgroups.Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis.Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
P2860
Q21089802-F01FE7D5-5048-4736-930B-6762040272D5Q21261272-4355A854-7C50-4EA8-B155-91F93D69E0D4Q24658633-3FE8D1CF-772C-4DC1-9A57-AEBA51F22299Q26862681-329B0B15-140D-46CB-9DB4-7BCB01E2B4A1Q27020973-2FDAC558-FFD0-4D06-A59D-A4DBEBD8DEC4Q28076200-5072AF15-A219-4170-AC35-89F2A91D0A7BQ28077637-8B436481-4E37-4D5E-B475-B3C69F6B8760Q28079118-2150C20D-C97E-4601-81AB-E8B6FB7C87E7Q28538685-68CC268C-BD43-427F-BF7B-6E5885DC15B7Q30313653-F1704138-0D6A-4BD8-9436-A33F17BE2C69Q30317579-67BFC81A-9C3D-449D-BB95-522869FE901FQ30901352-525A80A1-EE0F-47B0-BDA2-EB51642F29EDQ31132241-5760E67F-C506-4B02-8B22-D6E689134D8FQ31141334-7B525D71-E6E3-4E5C-B234-2E88C76A1F19Q33556608-8F6005AC-E40E-4C70-B52E-45998D3A03DAQ33559365-65740BEE-F690-477B-AC1C-2CAE8B74EFD8Q33684843-D7746DDD-1269-4648-94AF-1D23FB9F3E1EQ33827057-AB96AF36-32BB-4C31-88DB-78F60DC83AAEQ33834198-87D1FB50-8F0C-4725-9CE9-BCA21CFD749AQ33843799-0141776F-F8BE-41F0-8F80-A7DF7C1DFEFFQ34042640-7FD5E297-29E2-438C-B563-2BC31703C09DQ34075697-18DFBCE0-F235-467C-A07A-F6F1E81B9E8BQ34271033-155389D4-CD5E-4BE6-A194-5E57DE77FDFCQ34325544-6BFA2C2E-660C-432C-9D42-1ED7387A7163Q34395838-3E7813CB-1169-4560-9D02-D666690910D3Q34427347-688ED280-2B7D-4C9E-A75A-E00E7DC84F73Q34519347-5DF74555-90B9-494F-9222-D33938771774Q34657656-023209CE-77A9-464B-BECE-BD6EFD347155Q34797928-E22A125B-A71F-4C1F-BC62-8A234BA85348Q34897615-1F29F353-4EC3-4DA4-B2DA-B06042F8ED31Q35008290-2DE94FB0-3F45-4C1A-B9B7-F57347A38F90Q35018599-F250ACC3-484F-449C-A92D-C1426567B4E9Q35018949-8DCE8157-6685-4B6D-898E-B1C87A76018AQ35124596-DADB306B-24C2-41B1-8BD0-9C1A96C2D4E2Q35180940-835D05BE-23F9-40F2-8864-0540E90E4D55Q35194064-5861ADC5-E6D6-4AD9-A26C-D56FAA5ABFFFQ35446364-3EA75200-B554-45CB-B3C7-7214BFA55D50Q35475576-B6506F6E-73C5-42C0-A75A-4FDE9DDDB2F5Q35750136-5C208191-DF92-4B5B-A130-EAFDFEA29B9AQ35752868-3134D449-FF30-42F9-9ED8-48D580CEA4AC
P2860
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A new molecular predictor of d ...... ntional clinical risk factors.
@en
A new molecular predictor of d ...... ntional clinical risk factors.
@nl
type
label
A new molecular predictor of d ...... ntional clinical risk factors.
@en
A new molecular predictor of d ...... ntional clinical risk factors.
@nl
prefLabel
A new molecular predictor of d ...... ntional clinical risk factors.
@en
A new molecular predictor of d ...... ntional clinical risk factors.
@nl
P2093
P1476
A new molecular predictor of d ...... ntional clinical risk factors.
@en
P2093
Achim Rody
Andrea Jelen
Christa Freibauer
Christian F Singer
EP Investigators
Florian Fitzal
Fritz Jänicke
Guido Hennig
Heinz Kölbl
Inke S Feder
P304
P356
10.1158/1078-0432.CCR-11-0926
P407
P577
2011-08-01T00:00:00Z